Remote HEOR Director – Oncology/Prostate Assets

Scorpion Therapeutics; United States; Hybrid; USD 150,000 - 230,000; Full time

Benefits offered by this job

Remote work 25–30% travel

Job summary

Lantheus is seeking a Lead Health Economics and Outcomes Research (HEOR) professional to oversee the prostate franchise evidence strategy across the product lifecycle. You will collaborate with Commercial, Medical Affairs, and R&D to shape value demonstrations.

The role requires 7+ years of HEOR expertise, leadership, and strong communication skills, with knowledge of US HTA and payer landscapes. Remote work with 25–30% travel is expected.

Qualifications

• MS or MPH in health-related fields required.
• 7+ years HEOR experience across methodologies.
• Expertise in claims, EHR, registries, pharmacoeconomic modeling, and literature synthesis.
• Strong leadership, communication, and project management skills.
• Knowledge of US regulatory, HTA, and payer landscapes.

Responsibilities

• Establish cross-functional HEOR partnerships
• Design and oversee research projects (including secondary database analyses, modeling, and literature reviews)
• Develop fit-for-purpose HEOR strategies for pipeline and in-line assets
• Communicate findings to internal teams and external stakeholders
• Support field materials and payor guidance

Skills

HEOR leadership

Cross-functional collaboration

Research design & analyses

Communication & presentation

Project management

Education

MS or MPH in health-related fields

Tools

Claims data analysis

EHR data analysis

Pharmacoeconomic modeling

Literature synthesis

Job description

Lantheus is seeking a Lead Health Economics and Outcomes Research (HEOR) professional to oversee the prostate franchise evidence strategy across the product lifecycle. You will collaborate with Commercial, Medical Affairs, and R&D to shape value demonstrations.

The role requires 7+ years of HEOR expertise, leadership, and strong communication skills, with knowledge of US HTA and payer landscapes. Remote work with 25–30% travel is expected.